Yokohama Minami Kyosai Hospital
Welcome,         Profile    Billing    Logout  
 3 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Heffernan, Michael P
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

Completed
3
226
Europe, Canada, US, RoW
Bentracimab (PB2452) Infusion
SFJ Pharmaceuticals, Inc.
Hemorrhage, Urgent Surgery, Invasive Procedure
09/24
09/24
BRAIN-AF, NCT02387229: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

Terminated
3
1238
Canada
Rivaroxaban, Xarelto, standard of care
Montreal Heart Institute, Canadian Stroke Prevention Intervention Network, The Montreal Health Innovations Coordinating Center (MHICC), Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma, Montreal Heart Institute Foundation, Canadian Institutes of Health Research (CIHR), Hewitt Foundation
ATRIAL FIBRILLATION
05/24
05/24
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruiting
2
456
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
Khaykin, Yaariv
REFINE-ICD, NCT00673842: Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

Active, not recruiting
3
700
Europe, Canada, US, RoW
Implantable Cardioverter Defibrillator + Usual Care, Implantable Cardioverter Defibrillator, ICD, Usual care, Standard medical therapy alone
University of Calgary, Canadian Institutes of Health Research (CIHR), Alberta Innovation and Science, Medtronic, GE Healthcare, Cardiac Arrhythmia Network of Canada, Accelerating Clinical Trials Consortium
Myocardial Infarction, Sudden Death
12/24
12/24
BRAIN-AF, NCT02387229: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

Terminated
3
1238
Canada
Rivaroxaban, Xarelto, standard of care
Montreal Heart Institute, Canadian Stroke Prevention Intervention Network, The Montreal Health Innovations Coordinating Center (MHICC), Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma, Montreal Heart Institute Foundation, Canadian Institutes of Health Research (CIHR), Hewitt Foundation
ATRIAL FIBRILLATION
05/24
05/24
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruiting
2
456
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
NCT05983484: Holter Versus Skiin Garments

Completed
N/A
53
Canada
Skiin Underwear, PocketECG
Myant Medical Corp., Partners in Advanced Cardiac Evaluation
Cardiac Arrhythmia
02/24
02/24
NCT04061603: iCLAS™ for Persistent Atrial Fibrillation

Active, not recruiting
N/A
200
Europe, Canada, US
Adagio AF Cryoablation System (iCLAS™)
Adagio Medical
Persistent Atrial Fibrillation
08/23
08/24
ADVENT PAS, NCT06431815: ADVENT Post-Approval Study

Recruiting
N/A
220
Canada, US, RoW
FARAPULSE™ Pulsed Field Ablation System, FARAWAVE™ Pulsed Field Ablation Catheter
Boston Scientific Corporation
Paroxysmal Atrial Fibrillation
10/28
10/29
LAAOS-4, NCT05963698: The Fourth Left Atrial Appendage Occlusion Study

Recruiting
N/A
4000
Europe, Canada, US
WATCHMAN device
Hamilton Health Sciences Corporation, McMaster University, Population Health Research Institute, Boston Scientific Corporation
Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
09/29
12/29
Suzuki, Makoto
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruiting
2
456
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
Vizel, Saul
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruiting
2
456
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
Manyari, Dante
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruiting
2
456
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25

Download Options